CMA fines pharma companies for restricting drug supplies
The UK’s antitrust watchdog has fined four pharmaceutical companies and a private equity group more than £35 million for agreeing to limit the supply of an anti-nausea tablet to the National Health Service, causing prices to rise by 700%.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.